Intravitreal bevacizumab (Avastin) for the treatment of cystoid macular edema in Behçet disease.
OBJECTIVE
To investigate the effect of bevacizumab on cystoid macular edema in Behçet disease.


METHODS
Twelve eyes of 11 patients with Behçet disease underwent optical coherence tomography, fluorescein angiography, and visual acuity measurement before and after the intravitreal injection of Avastin to evaluate its effect.


RESULTS
The visual acuity improved in 7 eyes. Foveal thickness and macular volume did not show statistically significant differences. Fluorescein angiography reduced in grading in 4 patients and was deteriorated in 2.


CONCLUSIONS
The intravitreal injection of Avastin could be effective in the improvement of the vision in patients with uveitis secondary to Behçet disease.
Mirshahi
Ahmad
A
Tehran University of Medical Sciences, Tehran, Iran.
Namavari
Abed
A
Djalilian
Ali
A
Moharamzad
Yashar
Y
Chams
Hormoz
H
D000293:Adolescent; D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001528:Behcet Syndrome / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D000068258:Bevacizumab; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab